Company Overview
| Stock Name | Transcenta-B |
|---|---|
| Stock Code | 06628 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家集發現、研究、開發、製造及業務拓展能力為一體的臨床階段生物製藥公司,專注腫瘤、腎病及骨骼疾病等領域的抗體管線。 |
| Listing Date | 2021-09-29 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國蘇州星湖街218號生物納米園B6-501室,郵政編碼215123 |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.transcenta.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 16.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2021-09-14 to 2021-09-17 |
| Global Offering Shares | 40,330,000 shares |
| HK Public Offer Shares (Initial) | 4,033,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 36,297,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 445,331,917 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 69.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 645,280,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 670.4M |
| Est. Threshold | HK$ 9.69B |
| Analysis Result | HK market cap below threshold, need +1346% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 7,125,310,672 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損約人民幣322.9百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 70,647,000 |
| Listing Expenses / Funds Raised | ~10.95% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Revenue | 44,140 | 80,980 |
| Cost of sales | -37,226 | -62,778 |
| Gross profit | 6,914 | 18,202 |
| Other income and gains, net | -85,545 | 38,689 |
| Selling and distribution expenses | -1,302 | -2,759 |
| Administrative expenses | -121,616 | -155,190 |
| Net finance costs | -10,408 | -16,070 |
| Share of associates and JVs | 0 | 0 |
| Profit before tax | -426,520 | -323,010 |
| Income tax expense | -10,834 | 110 |
| Profit for the year | -437,354 | -322,900 |
| Profit attributable to owners | -395,256 | -316,626 |
Balance Sheet
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Cash and cash equivalents | 458,100 | 813,592 | 1,038,373 |
| Trade and bills receivables | 18,721 | 31,635 | 33,476 |
| Inventories | 6,315 | 7,901 | 11,746 |
| Total current assets | 487,945 | 891,457 | 1,138,317 |
| Total assets | 1,565,715 | 2,090,924 | 2,345,754 |
| Total current liabilities | 149,979 | 194,537 | 211,287 |
| Total liabilities | 2,201,875 | 2,907,169 | 3,228,576 |
| Total equity | -636,160 | -816,245 | -882,822 |
| Equity attributable to owners | -836,967 | -816,245 | -882,822 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021-03 |
|---|---|---|---|
| Net cash from operating activities | -234,960 | -174,398 | |
| Net cash from investing activities | -232,280 | -57,738 | |
| Net cash from financing activities | 551,210 | 967,401 | |
| Net increase in cash | 83,970 | 735,265 | |
| Depreciation of PP&E | 34,040 | 33,382 | 7,806 |
| Depreciation of right-of-use assets | 5,999 | 8,140 | 1,329 |
| Amortisation of intangible assets | 601 | 606 | 116 |
| Purchase of PP&E | -154,735 | -63,329 | -12,720 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 13.24 |
|---|---|
| First Day Open | HK$ 13.0 |
| First Day Change | -17.25% |
| First Day Volume | 11079000.0 |
| First Day Turnover | 143255000.0 |
| Use of Proceeds | 1、82%或約471.0百萬港元用于我們管線候選產品的研發、為進行中及計劃中的臨床及臨床前試驗、籌備注冊備案以及其他與商業化我們四款主打產品有關的步驟或活動撥資;
2、8%或約46.0百萬港元用于為擴充管線及開發技術的業務發展撥資;
3、10%或約57.4百萬港元用作一般營運資金及一般營運費用。 |
Underwriting Syndicate
Overall Coordinators (4)
Joint Bookrunners (4)
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Aranda Investments Pte. Ltd. | 33,032,000 HKD | — | 5.12% | — | 6 months | 2022-03-29 |
| 2 | LAV Amber Limited | 52,856,000 HKD | — | 8.19% | — | 6 months | 2022-03-29 |
| 3 | QH Oil Investments LLC | 165,200,000 HKD | — | 25.60% | — | 6 months | 2022-03-29 |
| 4 | 中国国有企业结构调整基金股份有限公司 | 198,240,000 HKD | — | 30.72% | — | 6 months | 2022-03-29 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 趙奕寧 | — |
| Company Secretary | 朱達、梁君慧 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 錢雪明博士(約12.84%)、HSBC Trust Company (Delaware) National Association(約10.25%)、Yi Shi(透過LAV集團,約15.10%) |
|---|




